Clinical Research Directory
Browse clinical research sites, groups, and studies.
Opzelura Experience Study
Sponsor: Wake Forest University Health Sciences
Summary
Atopic dermatitis is a common multifactorial skin disease. Topicals are the mainstay of treatment, but adherence to topicals is often abysmal, possibly worsened by the complexity of recommended treatment algorithms. Giving patients a simple, one drug approach may be advantageous.
Key Details
Gender
All
Age Range
2 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-08
Completion Date
2027-10
Last Updated
2026-07-14
Healthy Volunteers
No
Conditions
Interventions
ruxolitinib
patients are directed to apply topical ruxolitinib (Opzelura) twice daily to all affected areas until clear, then as needed
ruxolitinib and an Eczema Action Plan
patients will be directed to apply topical ruxolitinib (Opzelura) twice daily to all affected areas until clear, then as needed. Patients will also be provided an Eczema Action Plan (EAP) with recommended lifestyle recommendations, including what cleanser to use, allergen avoidance, use of moisturizers, and bathing practices as determined by disease severity
Locations (1)
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States